about
Toward Precision Medicine: A Cancer Molecular Subtyping Nano-Strategy for RNA Biomarkers in Tumor and Urine.Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.Precision Medicine and Men's Health.
P2860
description
im April 2015 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 10 April 2015
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2015
@uk
name
Prioritizing precision medicine for prostate cancer
@en
Prioritizing precision medicine for prostate cancer
@nl
type
label
Prioritizing precision medicine for prostate cancer
@en
Prioritizing precision medicine for prostate cancer
@nl
prefLabel
Prioritizing precision medicine for prostate cancer
@en
Prioritizing precision medicine for prostate cancer
@nl
P2860
P356
P1433
P1476
Prioritizing precision medicine for prostate cancer
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDV179
P577
2015-04-10T00:00:00Z